Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2004 Jun;13(3):181–187. doi: 10.1080/09511920410001713529

Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms.

Joanna Balding 1, Wendy J Livingstone 1, Judith Conroy 1, Lesley Mynett-Johnson 1, Donald G Weir 1, Nasir Mahmud 1, Owen P Smith 1
PMCID: PMC1781555  PMID: 15223609

Abstract

The mechanisms responsible for development of inflammatory bowel disease (IBD) have not been fully elucidated, although the main cause of disease pathology is attributed to up-regulated inflammatory processes. The aim of this study was to investigate frequencies of polymorphisms in genes encoding pro-inflammatory and anti-inflammatory markers in IBD patients and controls. We determined genotypes of patients with IBD (n= 172) and healthy controls (n= 389) for polymorphisms in genes encoding various cytokines (interleukin (IL)-1beta, IL-6, tumour necrosis factor (TNF), IL-10, IL-1 receptor antagonist). Association of these genotypes to disease incidence and pathophysiology was investigated. No strong association was found with occurrence of IBD. Variation was observed between the ulcerative colitis study group and the control population for the TNF-alpha-308 polymorphism (p= 0.0135). There was also variation in the frequency of IL-6-174 and TNF-alpha-308 genotypes in the ulcerative colitis group compared with the Crohn's disease group (p= 0.01). We concluded that polymorphisms in inflammatory genes are associated with variations in IBD phenotype and disease susceptibility. Whether the polymorphisms are directly involved in regulating cytokine production, and consequently pathophysiology of IBD, or serve merely as markers in linkage disequilibrium with susceptibility genes remains unclear.

Full Text

The Full Text of this article is available as a PDF (108.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bouma G., Xia B., Crusius J. B., Bioque G., Koutroubakis I., Von Blomberg B. M., Meuwissen S. G., Peña A. S. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin Exp Immunol. 1996 Mar;103(3):391–396. doi: 10.1111/j.1365-2249.1996.tb08292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cominelli F., Nast C. C., Duchini A., Lee M. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology. 1992 Jul;103(1):65–71. doi: 10.1016/0016-5085(92)91096-m. [DOI] [PubMed] [Google Scholar]
  3. Craggs A., West S., Curtis A., Welfare M., Hudson M., Donaldson P., Mansfield J. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand J Gastroenterol. 2001 Nov;36(11):1173–1178. doi: 10.1080/00365520152584806. [DOI] [PubMed] [Google Scholar]
  4. Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995 Feb;99(2):303–310. doi: 10.1111/j.1365-2249.1995.tb05549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dominici Roberto, Malferrari Giulia, Mariani Claudio, Grimaldi Luigi, Biunno Ida. The Interleukin 1-beta exonic (+3953) polymorphism does not alter in vitro protein secretion. Exp Mol Pathol. 2002 Oct;73(2):139–141. doi: 10.1006/exmp.2002.2435. [DOI] [PubMed] [Google Scholar]
  6. Evans R. C., Clarke L., Heath P., Stephens S., Morris A. I., Rhodes J. M. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997 Dec;11(6):1031–1035. doi: 10.1046/j.1365-2036.1997.00251.x. [DOI] [PubMed] [Google Scholar]
  7. Fang X. M., Schröder S., Hoeft A., Stüber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med. 1999 Jul;27(7):1330–1334. doi: 10.1097/00003246-199907000-00024. [DOI] [PubMed] [Google Scholar]
  8. Fijen J. W., Tulleken J. E., Hepkema B. G., van der Werf T. S., Ligtenberg J. J., Zijlstra J. G. The influence of tumor necrosis factor-alpha and interleukin-10 gene promoter polymorphism on the inflammatory response in experimental human endotoxemia. Clin Infect Dis. 2001 Oct 4;33(9):1601–1603. doi: 10.1086/323197. [DOI] [PubMed] [Google Scholar]
  9. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J. S., Humphries S., Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998 Oct 1;102(7):1369–1376. doi: 10.1172/JCI2629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gonzalez S., Martinez-Borra J., Torre-Alonso J. C., Gonzalez-Roces S., Sanchez del Río J., Rodriguez Pérez A., Brautbar C., López-Larrea C. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. 1999 May;42(5):1010–1016. doi: 10.1002/1529-0131(199905)42:5<1010::AID-ANR21>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
  11. Greenberg G. R., Feagan B. G., Martin F., Sutherland L. R., Thomson A. B., Williams C. N., Nilsson L. G., Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996 Jan;110(1):45–51. doi: 10.1053/gast.1996.v110.pm8536887. [DOI] [PubMed] [Google Scholar]
  12. Gross V., Andus T., Caesar I., Roth M., Schölmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology. 1992 Feb;102(2):514–519. doi: 10.1016/0016-5085(92)90098-j. [DOI] [PubMed] [Google Scholar]
  13. Hacker U. T., Gomolka M., Keller E., Eigler A., Folwaczny C., Fricke H., Albert E., Loeschke K., Endres S. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut. 1997 May;40(5):623–627. doi: 10.1136/gut.40.5.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Humphries S. E., Luong L. A., Ogg M. S., Hawe E., Miller G. J. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001 Dec;22(24):2243–2252. doi: 10.1053/euhj.2001.2678. [DOI] [PubMed] [Google Scholar]
  15. Klein W., Tromm A., Griga T., Fricke H., Folwaczny C., Hocke M., Eitner K., Marx M., Epplen J. T. The polymorphism at position -174 of the IL-6 gene is not associated with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2001 Jan;13(1):45–47. doi: 10.1097/00042737-200101000-00008. [DOI] [PubMed] [Google Scholar]
  16. Klein W., Tromm A., Griga T., Fricke H., Folwaczny C., Hocke M., Eitner K., Marx M., Runte M., Epplen J. T. The IL-10 gene is not involved in the predisposition to inflammatory bowel disease. Electrophoresis. 2000 Nov;21(17):3578–3582. doi: 10.1002/1522-2683(200011)21:17<3578::AID-ELPS3578>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  17. Koss K., Satsangi J., Fanning G. C., Welsh K. I., Jewell D. P. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 2000 Feb;1(3):185–190. doi: 10.1038/sj.gene.6363657. [DOI] [PubMed] [Google Scholar]
  18. Louis E., Satsangi J., Roussomoustakaki M., Parkes M., Fanning G., Welsh K., Jewell D. Cytokine gene polymorphisms in inflammatory bowel disease. Gut. 1996 Nov;39(5):705–710. doi: 10.1136/gut.39.5.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lowe Peter R., Galley Helen F., Abdel-Fattah Ashraf, Webster Nigel R. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med. 2003 Jan;31(1):34–38. doi: 10.1097/00003246-200301000-00005. [DOI] [PubMed] [Google Scholar]
  20. Mansfield J. C., Holden H., Tarlow J. K., Di Giovine F. S., McDowell T. L., Wilson A. G., Holdsworth C. D., Duff G. W. Novel genetic association between ulcerative colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology. 1994 Mar;106(3):637–642. doi: 10.1016/0016-5085(94)90696-3. [DOI] [PubMed] [Google Scholar]
  21. Mark L. L., Haffajee A. D., Socransky S. S., Kent R. L., Jr, Guerrero D., Kornman K., Newman M., Stashenko P. Effect of the interleukin-1 genotype on monocyte IL-1beta expression in subjects with adult periodontitis. J Periodontal Res. 2000 Jun;35(3):172–177. doi: 10.1034/j.1600-0765.2000.035003172.x. [DOI] [PubMed] [Google Scholar]
  22. Messer G., Spengler U., Jung M. C., Honold G., Blömer K., Pape G. R., Riethmüller G., Weiss E. H. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991 Jan 1;173(1):209–219. doi: 10.1084/jem.173.1.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mira J. P., Cariou A., Grall F., Delclaux C., Losser M. R., Heshmati F., Cheval C., Monchi M., Teboul J. L., Riché F. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA. 1999 Aug 11;282(6):561–568. doi: 10.1001/jama.282.6.561. [DOI] [PubMed] [Google Scholar]
  24. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995 Jul;30(7):699–706. doi: 10.3109/00365529509096316. [DOI] [PubMed] [Google Scholar]
  25. Nadel S., Newport M. J., Booy R., Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996 Oct;174(4):878–880. doi: 10.1093/infdis/174.4.878. [DOI] [PubMed] [Google Scholar]
  26. Nauck Markus, Winkelmann Bernhard R., Hoffmann Michael M., Böhm Bernhard O., Wieland Heinrich, März Winfried. The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med (Berl) 2002 Jun 21;80(8):507–513. doi: 10.1007/s00109-002-0354-2. [DOI] [PubMed] [Google Scholar]
  27. Nemetz A., Nosti-Escanilla M. P., Molnár T., Köpe A., Kovács A., Fehér J., Tulassay Z., Nagy F., García-González M. A., Peña A. S. IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease. Immunogenetics. 1999 Jun;49(6):527–531. doi: 10.1007/s002510050530. [DOI] [PubMed] [Google Scholar]
  28. Pociot F., Briant L., Jongeneel C. V., Mölvig J., Worsaae H., Abbal M., Thomsen M., Nerup J., Cambon-Thomsen A. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol. 1993 Jan;23(1):224–231. doi: 10.1002/eji.1830230135. [DOI] [PubMed] [Google Scholar]
  29. Pociot F., Mølvig J., Wogensen L., Worsaae H., Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest. 1992 Jun;22(6):396–402. doi: 10.1111/j.1365-2362.1992.tb01480.x. [DOI] [PubMed] [Google Scholar]
  30. Roth M. P., Petersen G. M., McElree C., Vadheim C. M., Panish J. F., Rotter J. I. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology. 1989 Apr;96(4):1016–1020. doi: 10.1016/0016-5085(89)91618-1. [DOI] [PubMed] [Google Scholar]
  31. Santtila S., Savinainen K., Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol. 1998 Mar;47(3):195–198. doi: 10.1046/j.1365-3083.1998.00300.x. [DOI] [PubMed] [Google Scholar]
  32. Schlüter Bernhard, Raufhake Carsten, Erren Michael, Schotte Heiko, Kipp Frank, Rust Stephan, Van Aken Hugo, Assmann Gerd, Berendes Elmar. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med. 2002 Jan;30(1):32–37. doi: 10.1097/00003246-200201000-00005. [DOI] [PubMed] [Google Scholar]
  33. Schreiber S., Heinig T., Thiele H. G., Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995 May;108(5):1434–1444. doi: 10.1016/0016-5085(95)90692-4. [DOI] [PubMed] [Google Scholar]
  34. Shanahan Fergus. Crohn's disease. Lancet. 2002 Jan 5;359(9300):62–69. doi: 10.1016/S0140-6736(02)07284-7. [DOI] [PubMed] [Google Scholar]
  35. Stevens C., Walz G., Singaram C., Lipman M. L., Zanker B., Muggia A., Antonioli D., Peppercorn M. A., Strom T. B. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992 Jun;37(6):818–826. doi: 10.1007/BF01300378. [DOI] [PubMed] [Google Scholar]
  36. Stüber F., Petersen M., Bokelmann F., Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996 Mar;24(3):381–384. doi: 10.1097/00003246-199603000-00004. [DOI] [PubMed] [Google Scholar]
  37. Tagore A., Gonsalkorale W. M., Pravica V., Hajeer A. H., McMahon R., Whorwell P. J., Sinnott P. J., Hutchinson I. V. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens. 1999 Oct;54(4):386–390. doi: 10.1034/j.1399-0039.1999.540408.x. [DOI] [PubMed] [Google Scholar]
  38. Targan S. R., Hanauer S. B., van Deventer S. J., Mayer L., Present D. H., Braakman T., DeWoody K. L., Schaible T. F., Rutgeerts P. J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997 Oct 9;337(15):1029–1035. doi: 10.1056/NEJM199710093371502. [DOI] [PubMed] [Google Scholar]
  39. Tarlow J. K., Blakemore A. I., Lennard A., Solari R., Hughes H. N., Steinkasserer A., Duff G. W. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993 May;91(4):403–404. doi: 10.1007/BF00217368. [DOI] [PubMed] [Google Scholar]
  40. Thomas T. K., Will P. C., Srivastava A., Wilson C. L., Harbison M., Little J., Chesonis R. S., Pignatello M., Schmolze D., Symington J. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions. 1991 Sep;34(1-2):187–190. doi: 10.1007/BF01993274. [DOI] [PubMed] [Google Scholar]
  41. Tountas N. A., Casini-Raggi V., Yang H., Di Giovine F. S., Vecchi M., Kam L., Melani L., Pizarro T. T., Rotter J. I., Cominelli F. Functional and ethnic association of allele 2 of the interleukin-1 receptor antagonist gene in ulcerative colitis. Gastroenterology. 1999 Oct;117(4):806–813. doi: 10.1016/s0016-5085(99)70338-0. [DOI] [PubMed] [Google Scholar]
  42. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997 Feb;24(1):1–8. doi: 10.1111/j.1365-2370.1997.tb00001.x. [DOI] [PubMed] [Google Scholar]
  43. Tysk C., Lindberg E., Järnerot G., Flodérus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut. 1988 Jul;29(7):990–996. doi: 10.1136/gut.29.7.990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Vatay Agnes, Bene László, Kovács Agota, Prohászka Zoltán, Szalai Csaba, Romics László, Fekete Béla, Karádi István, Füst George. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003 Jun 14;55(4):247–252. doi: 10.1007/s00251-003-0575-8. [DOI] [PubMed] [Google Scholar]
  45. Warzocha K., Ribeiro P., Bienvenu J., Roy P., Charlot C., Rigal D., Coiffier B., Salles G. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998 May 15;91(10):3574–3581. [PubMed] [Google Scholar]
  46. Whichelow C. E., Hitman G. A., Raafat I., Bottazzo G. F., Sachs J. A. The effect of TNF*B gene polymorphism on TNF-alpha and -beta secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur J Immunogenet. 1996 Dec;23(6):425–435. doi: 10.1111/j.1744-313x.1996.tb00133.x. [DOI] [PubMed] [Google Scholar]
  47. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O., Duff G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. van Deventer S. J., Elson C. O., Fedorak R. N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997 Aug;113(2):383–389. doi: 10.1053/gast.1997.v113.pm9247454. [DOI] [PubMed] [Google Scholar]
  49. van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES